Hologic, Inc.
General ticker "HOLX" information:
- Sector: Health Care
- Industry: Health Care Equipment & Supplies
- Capitalization: $15.0B (TTM average)
Hologic, Inc. follows the US Stock Market performance with the rate: 41.8%.
Estimated limits based on current volatility of 0.2%: low 74.80$, high 75.15$
Factors to consider:
- Company included in S&P500 list
- Total employees count: 7063 (+1.0%) as of 2024
- US accounted for 76.9% of revenue in the fiscal year ended 2023-09-30
- Top business risk factors: Pandemic risks, Supply chain disruptions, Product liability, Regulatory and compliance, Integration challenges
- Earnings for 12 months up through Q4 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-09-30 to 2026-09-30
- 2024-09-30 to 2025-09-30 estimated range: [72.39$, 96.00$]
- 2025-09-30 to 2026-09-30 estimated range: [79.06$, 104.29$]
Financial Metrics affecting the HOLX estimates:
- Negative: with PPE of 19.9 at the end of fiscal year the price was very high
- Positive: Operating profit margin, % of 21.90 > 18.64
- Positive: Return on assets ratio (scaled to [-100,100]) of 7.94 > 6.04
- Negative: Operating cash flow per share per price, % of 6.71 <= 6.82
- Positive: 41.86 < Shareholder equity ratio, % of 56.03 <= 63.39
- Negative: 0.01 < Interest expense per share per price, % of 0.64
- Negative: Industry operating cash flow per share per price (median), % of 0 <= 5.52
- Positive: -8.75 < Industry operating profit margin (median), % of -8.00
- Positive: Industry inventory ratio change (median), % of 0.28 <= 0.28
Short-term HOLX quotes
Long-term HOLX plot with estimates
Financial data
| YTD | 2022-09-30 | 2023-09-30 | 2024-09-30 |
|---|---|---|---|
| Operating Revenue | $4,862.80MM | $3,978.70MM | $4,030.30MM |
| Operating Expenses | $3,222.60MM | $3,310.30MM | $3,147.70MM |
| Operating Income | $1,640.20MM | $668.40MM | $882.60MM |
| Non-Operating Income | $-52.00MM | $7.70MM | $-17.50MM |
| Interest Expense | $95.10MM | $111.10MM | $122.10MM |
| R&D Expense | $283.40MM | $294.30MM | $272.80MM |
| Income(Loss) | $1,588.20MM | $676.10MM | $865.10MM |
| Taxes | $286.20MM | $220.10MM | $75.60MM |
| Profit(Loss)* | $1,302.00MM | $456.00MM | $789.50MM |
| Stockholders Equity | $4,876.20MM | $5,016.90MM | $5,130.00MM |
| Inventory | $623.70MM | $617.60MM | $679.80MM |
| Assets | $9,071.20MM | $9,139.30MM | $9,156.00MM |
| Operating Cash Flow | $2,125.70MM | $1,051.20MM | $1,285.20MM |
| Capital expenditure | $127.20MM | $150.20MM | $140.20MM |
| Investing Cash Flow | $-206.30MM | $-152.10MM | $-781.00MM |
| Financing Cash Flow | $-756.00MM | $-483.20MM | $-1,108.60MM |
| Earnings Per Share** | $5.18 | $1.85 | $3.35 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.